ContractWarrant Agreement • May 15th, 2019 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances) • Delaware
THIS WARRANT, AND THE SECURITIES ISSUABLE UPON THE EXERCISE OF THIS WARRANT, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT, OR ANY APPLICABLE STATE SECURITIES LAWS.
X4 PHARMACEUTICALS, INC. NON-QUALIFIED OPTION AGREEMENT (DIRECTOR GRANTS)Non-Qualified Option Agreement • May 15th, 2019 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances)
This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
X4 PHARMACEUTICALS, INC. INCENTIVE STOCK OPTION AGREEMENTIncentive Stock Option Agreement • May 15th, 2019 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances)
X4 Pharmaceuticals, Inc. (the “Company”) hereby grants the following stock option pursuant to its 2017 Equity Incentive Plan (the Arsanis, Inc. 2017 Equity Incentive Plan). The terms and conditions attached hereto are also a part hereof.
X4 PHARMACEUTICALS, INC. RESTRICTED STOCK AGREEMENTRestricted Stock Agreement • May 15th, 2019 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances) • Delaware
X4 Pharmaceuticals, Inc. (the “Company”) has selected you to receive the following restricted stock award pursuant to its 2017 Equity Incentive Plan (the Arsanis, Inc. 2017 Equity Incentive Plan). The terms and conditions attached hereto are also a part hereof.
